

**ANTIBIOTICS, GI and RELATED AGENTS PRIOR AUTHORIZATION FORM** (form effective 1/8/2024)

Prior authorization guidelines for **Antibiotics, GI and Related Agents** and **Quantity Limits/Daily Dose Limits** are available on Geisinger Health Plan's website at <https://healthplan.geisinger.org/pharmacy/pharmacy.aspx?strip=true&style=OneGeisinger>

<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	# of pages: _____	Prescriber name:	
Name of office contact:			Specialty:	
Contact's phone number:			NPI:	State license #:
LTC facility contact/phone:			Street address:	
Beneficiary name:			City/State/Zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:	

**CLINICAL INFORMATION**

Drug requested:	Strength:	Dosage form:	
Dose/directions:		Quantity:	Refills:
Diagnosis (submit documentation):		DX code ( <u>required</u> ):	

**Complete all sections that apply to the beneficiary and this request.**  
**Check all that apply and submit documentation for each item.**

**INITIAL requests**

<b>1. For treatment of HEPATIC ENCEPHALOPATHY:</b> <input type="checkbox"/> Has a history of trial and failure of or a contraindication or an intolerance to <u>lactulose</u>
<b>2. For treatment of TRAVELERS' DIARRHEA:</b> <input type="checkbox"/> Has a history of trial and failure of or a contraindication or an intolerance to <u>azithromycin</u>
<b>3. For treatment of IRRITABLE BOWEL SYNDROME WITH DIARRHEA:</b> <input type="checkbox"/> Requested medication is prescribed by or in consultation with a gastroenterologist
<b>4. For treatment of SMALL INTENSTINAL BACTERIAL OVERGROWTH:</b> <input type="checkbox"/> Requested medication is prescribed by or in consultation with a gastroenterologist
<b>5. For DIFICID (FIDAXOMICIN) for treatment of CLOSTRIDIoidES DIFFICILE INFECTION:</b> <input type="checkbox"/> Has at least one of the following risk factors associated with a high risk of recurrence of <i>Clostridioides difficile</i> infection: <input type="checkbox"/> 65 years of age or older <input type="checkbox"/> Clinically severe <i>Clostridioides difficile</i> infection (Zar score ≥2) <input type="checkbox"/> Immunocompromised status <input type="checkbox"/> Has a recurrent episode of <i>Clostridioides difficile</i> infection <input type="checkbox"/> Is prescribed Dificid (fidaxomicin) as a continuation of therapy upon inpatient discharge
<b>6. For ZINPLAVA (BEZLOTOXUMAB):</b> Beneficiary's weight (in kg): _____ kg

- ☐ Requested medication is prescribed by or in consultation with a gastroenterologist or infectious disease specialist
- ☐ Has a recent stool test that is positive for toxigenic *Clostridioides difficile*
- ☐ Has at least one of the following factors associated with a high risk of recurrence of *Clostridioides difficile* infection:
  - ☐ 65 years of age or older
  - ☐ Extended use of one or more systemic antibacterial drugs
  - ☐ Clinically severe *Clostridioides difficile* infection
  - ☐ At least one previous episode of *Clostridioides difficile* infection within the past six months
  - ☐ Documented history of at least two previous episodes of *Clostridioides difficile* infection
  - ☐ Immunocompromised status
  - ☐ Infected with a hypervirulent strain of *Clostridioides difficile* (ribotypes 027, 078, or 244)
- ☐ Will receive Zinplava (bezlotoxumab) in conjunction with an antibiotic regimen that is consistent with the standard of care for the treatment of *Clostridioides difficile* infection
- ☐ Has not received a prior course of treatment with Zinplava (bezlotoxumab)

**7. For ALL OTHER NON-PREFERRED Antibiotics, GI and Related Agents and for ALL OTHER INDICATIONS:**

- ☐ Has a history of trial and failure of or a contraindication or an intolerance to the preferred Antibiotics, GI and Related Agents that are approved or medically accepted for the treatment of the beneficiary's diagnosis

**RENEWAL requests**

**1. For treatment of IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D):**

- ☐ Had a successful initial treatment course
- ☐ Is experiencing recurrence of IBS-D symptoms
- ☐ Requested medication is prescribed by or in consultation with a gastroenterologist
- ☐ **Request is for XIFAXAN (RIFAXIMIN) and:**
  - ☐ Has not received 3 or more treatment courses of Xifaxan (rifaximin) in the beneficiary's lifetime

**2. For treatment of SMALL INTESTINAL BACTERIAL OVERGROWTH:**

- ☐ Requested medication is prescribed by or in consultation with a gastroenterologist

Please submit to PromptPA <https://ghp.promptpa.com> OR fax to Geisinger Health Plan at 570-271-5610 the completed form with required clinical documentation.

Prescriber Signature:

Date:

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.